West Pharma Guides FY Adjusted EPS to $9.38-$9.48
WST sits 78% above its 52-week low of $223.83.
Summary
West Pharmaceutical issued full-year adjusted EPS guidance of $9.31 to $9.41, alongside full-year sales guidance of $3.41 billion to $3.42 billion. The company also reported third-quarter adjusted EPS of $2.66. The guidance carries no comparison to prior guidance or consensus, so the direction versus expectations can't be judged from this alone. The stock trades near its 52-week high, which raises the bar for the print. This lands days after the October 26 8-K disclosing a new $950 million credit agreement ($750 million revolver plus $200 million term loan), so the balance sheet has fresh capacity behind it.
At the time of this announcement, WST was trading at $398.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $28.4B. The 52-week trading range was $223.83 to $404.99. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.